The tumor microenvironment is the complex ecosystem surrounding cancer cells, made up of blood vessels, immune cells, fibroblasts, signaling molecules and the extracellular matrix. Rather than being a passive backdrop, it actively shapes how tumors grow, invade, spread and respond to treatment.

Cancer cells continually interact with and remodel this microenvironment. They recruit blood vessels through pro angiogenic factors, creating an abnormal, leaky vasculature that both nourishes the tumor and impairs drug delivery. They also alter the extracellular matrix, changing its stiffness and composition to favor invasion and metastasis.

Immune cells are central players. Tumors attract and reprogram immune cells such as macrophages, T cells and myeloid derived suppressor cells. Instead of mounting an effective antitumor response, these cells often become immunosuppressive, secrete growth factors and promote angiogenesis. Hypoxia, a common feature caused by disorganized blood flow, further drives immune suppression and selects for more aggressive cancer cell clones.

Cancer associated fibroblasts help orchestrate many of these changes. They generate matrix components, secrete cytokines and chemokines and help establish niches that protect tumor cells from chemotherapy and radiotherapy. Together, these interactions create a protective, pro tumor niche.

Research has shifted from focusing solely on cancer cells to targeting components of the microenvironment. Strategies include normalizing tumor blood vessels, reprogramming or depleting protumor immune cells, blocking immune checkpoints, altering the extracellular matrix and targeting fibroblasts. By disrupting the supportive functions of the tumor microenvironment or restoring effective antitumor immunity, these approaches aim to improve treatment responses and overcome resistance in a wide range of cancers.